FearLess in NeuroOncology
NCT06989086
Recruiting
The overarching goal of this project is to assess the feasibility, acceptability, and appropriateness of recruitment methods, target population, and a waitlist design to finalize the protocol of FearLess in primary malignant brain tumor patients and caregivers
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Primary Malignant Brain Tumor, Glioblastoma (GBM), Astrocytoma, Oligodendroglioma, Caregiver
Register for Updates
Attention Bias Modification for the Improvement of Anxiety in Adolescent and Young Adult Cancer Survivors
NCT06682039
Recruiting
This clinical trial studies how well attention bias modification (ABM) improves anxiety in adolescent and young adult (AYA) cancer survivors. Cancer-related anxiety is the most prevalent mental health problem affecting AYA cancer survivors. Cancer-related anxiety is associated with long-term negative outcomes such as poor quality of life, depression, distress, substance use, sleep problems, fatigue, and pain. ABM uses techniques to help patients change the way they react to environmental trigger... Read More
Gender:
ALL
Ages:
Between 15 years and 29 years
Trial Updated:
08/21/2025
Locations: Fred Hutch/University of Washington/Seattle Children's Cancer Consortium, Seattle, Washington
Conditions: Childhood Hematopoietic and Lymphatic System Neoplasm, Childhood Malignant Solid Neoplasm
Register for Updates
A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam)
NCT06223360
Recruiting
The purpose of this study is to learn more about the safety, effectiveness and tolerability of the study drug called Benfotiamine which may delay or slow the progression of the symptoms of early Alzheimer's disease.
Gender:
ALL
Ages:
Between 50 years and 89 years
Trial Updated:
08/21/2025
Locations: St. Joseph's Hospital and Medical Center/Barrow Neurological Institute, Phoenix, Arizona +38 locations
Conditions: Alzheimer Disease
Register for Updates
A Study to Determine the Safety and Tolerability of AG-236 and How it is Absorbed, Broken Down, and Eliminated From the Body in Healthy Participants
NCT07075640
Recruiting
The primary purpose of this study is to assess the safety and tolerability of a single dose of AG-236 administered subcutaneously in healthy participants.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
08/21/2025
Locations: Fortrea Clinical Research Unit Inc., Madison, Wisconsin
Conditions: Healthy Participants
Register for Updates
A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer
NCT05999994
Recruiting
The main purpose of the master is to help the research sites and sponsor carry out several clinical trials more efficiently by providing a common research protocol. Individual clinical trials under this master protocol define drug/disease-specific research goals and activities to test them. New studies will be added as new drugs emerge against different cancers. Participation in the trial will depend on how long the benefit lasts.
Gender:
ALL
Ages:
Between 1 year and 39 years
Trial Updated:
08/21/2025
Locations: Childrens Hospital of Alabama, Birmingham, Alabama +71 locations
Conditions: Neoplasms, Child, Adolescent
Register for Updates
Dose Finding Study of [177Lu]Lu-NeoB in Newly Diagnosed Glioblastoma and in Recurrent Glioblastoma
NCT05739942
Recruiting
This study will investigate different doses of \[177Lu\]Lu-NeoB in combination with RT and TMZ in participants with newly diagnosed glioblastoma, with methylated or unmethylated promoter, to assess the safety and efficacy of \[177Lu\]Lu-NeoB in combination with the SoC and in recurrent glioblastoma as single agent, to identify the recommended dose and to also explore the safety of the PET imaging agent \[68Ga\]Ga-NeoB and characterize its uptake in the tumor area.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/21/2025
Locations: University of California LA, Los Angeles, California +21 locations
Conditions: Newly Diagnosed and Recurrent Glioblastoma
Register for Updates
Reducing Risk for Infective Endocarditis
NCT05721781
Recruiting
This clinical trial is studying if bacteria found in a participant's bloodstream after brushing their teeth can be prevented with a dental cleaning and more education on how to best brush and care for their teeth. One group of participants will have a dental cleaning and oral health instructions and the other group of participants will not. Researchers will compare the blood test results from the two groups to see if the education made a difference in preventing bacteria and how long it stays in... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/21/2025
Locations: Tufts University School of Dental Medicine and Tufts University Health Sciences Campus, Boston, Massachusetts +5 locations
Conditions: Bacteremia, Infective Endocarditis
Register for Updates
An Innovative Intervention for OUD Treatment
NCT04325659
Recruiting
The Bridge Device (BD) is a neuromodulator medical device that has been cleared by the FDA for Opioid Use Disorder (OUD) treatment. Importantly, medical devices reviewed by the FDA are cleared (based on safety) rather than approved (based on efficacy), which means the BD did not need to demonstrate efficacy before it became commercially available. As a result, the device was not required to have a sham-controlled trial for FDA clearance and there is no active research, to the investigators' know... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
08/21/2025
Locations: Behavioral Pharmacology Research Unit, Baltimore, Maryland
Conditions: Opioid-Related Disorders, Opioid Dependence, Opioid Addiction, Opioid Withdrawal
Register for Updates
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP)
NCT05653349
Recruiting
The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in maintaining platelet count ≥30 G/L in adult participants with primary ITP.
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
08/20/2025
Locations: Yuma Regional Medical Center, Yuma, Arizona +154 locations
Conditions: Primary Immune Thrombocytopenia (ITP)
Register for Updates
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
NCT05605899
Recruiting
The goal of this clinical study is to compare the study drug, axicabtagene ciloleucel, versus standard of care (SOC) in first-line therapy in participants with high-risk large B-cell lymphoma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: University of Alabama Hospital, Birmingham, Alabama +89 locations
Conditions: High-risk Large B-cell Lymphoma (LBCL)
Register for Updates
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
NCT07121946
Recruiting
This study is a first-in-human (FIH), Phase 1, multicenter, open-label study to determine the safety, tolerability, pharmacokinetics, pharmacodynamics, and evaluate the preliminary anti-tumor activity of LTZ-301 administered as a single agent in adult subjects with relapsed or refractory B-cell non-Hodgkin lymphoma
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/20/2025
Locations: Tennessee Oncology, Nashville, Tennessee
Conditions: Non-Hodgkin Lymphoma Refractory/ Relapsed, DLBCL - Diffuse Large B Cell Lymphoma, Mantle Cell Lymphoma (MCL), Follicular Lymphoma ( FL), Marginal Zone Lymphoma (MZL)
Register for Updates
Mandibular Advancement Device and Changes in Nocturia
NCT05562388
Recruiting
The main purpose of this study is to test is mandibular advacenment device (MAD) use is associated with reductions in nocturia.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
08/20/2025
Locations: University of Kentucky, Lexington, Kentucky
Conditions: Obstructive Sleep Apnea, Nocturia, OSA
Register for Updates